Scip & Savor for a Cure Fundraiser Benefits the International Myeloma Foundation (IMF) and Family Reach
October 27, 2022 08:45 ET
|
International Myeloma Foundation
STUDIO CITY, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announced the details of the recent fundraising celebration hosted by Fatima Scipione and her...
The Annual Miracles for Myeloma 5K Hybrid Run/Walk Celebrates 10th Anniversary
September 29, 2022 08:45 ET
|
International Myeloma Foundation
CLARK, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) -- The Annual Miracles for Myeloma 5K Hybrid Run/Walk will be celebrating its tenth anniversary this year. For the past nine years, this annual event has...
CURE Media Group Opens Nominations for Multiple Myeloma Heroes® Award Program
August 04, 2022 15:54 ET
|
CURE Media Group
The Recognition Will Honor Individuals Who Have Made a Significant Difference in the Lives of Those Affected by Multiple Myeloma CRANBURY, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- CURE Media...
Moving Mountains for Multiple Myeloma® Tackles Mt. Washington
July 01, 2022 09:03 ET
|
CURE Media Group
CRANBURY, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- Moving Mountains for Multiple Myeloma®, a program with the mission of raising funds and awareness for multiple myeloma research, will take the...
CORRECTION - Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
May 05, 2022 18:12 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Celyad Oncology SA (Euronext & Nasdaq: CYAD), please note that in the...
Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
May 05, 2022 16:05 ET
|
Celyad Oncology SA
Enrollment continues in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory multiple myeloma (r/r MM)Dialogue continues with...
Starton Therapeutics Provides Update on STAR-LLD Lenalidomide Clinical Program
May 04, 2022 07:00 ET
|
Starton Therapeutics, Inc.
Independent safety review approved dose escalation and initiation of next dosing cohortSTAR-LLD generally well tolerated in all subjects dosed to dateOn track to complete dosing of all cohorts in May...
Starton Therapeutics Announces Notice of Allowance for U.S. Patent Application Protecting Continuous Delivery of Lenalidomide and Other Immunomodulatory Agents
October 04, 2021 07:00 ET
|
Starton Therapeutics, Inc.
PARAMUS, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc., a clinical stage biotechnology company transforming standard of care therapies with proprietary dermal technologies, today...
Starton Therapeutics Announces Successful Results in STAR-LLD Toxicology Study: No Myelosuppression and Excellent Tolerability
September 30, 2021 07:10 ET
|
Starton Therapeutics, Inc.
PARAMUS, N.J., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc., a clinical stage biotechnology company transforming standard of care therapies with proprietary dermal technologies,...
Multiple Myeloma Pipeline Analysis Demonstrates Stunning Growth With A Gamut of Pharma Companies Involved Worldwide
May 18, 2021 20:20 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, May 18, 2021 (GLOBE NEWSWIRE) -- Multiple Myeloma Pipeline Analysis Demonstrates Stunning Growth with a Gamut of Pharma Companies Involved Worldwide The Multiple Myeloma...